[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

June 2013 | 217 pages | ID: P1836025D56EN

US$ 2,635.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Contract manufacturing for pharma - discover top companies' revenue prospects

How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.

That way you find information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.

There you also gain 141 tables, 58 charts, and five interviews with the industry.

Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:
  • Finished dosage formulations (FDF) manufacturing
  • Active pharmaceutical ingredients (API) production.
See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.

Company profiles - activities, results, competition, and prospects

Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:
  • Overview of the company's contract manufacturing services, including clients
  • Analysis of recent financial performance - overall revenue and that for CMO services
  • Assessment of developments - acquisitions, capacity expansions, new service offerings, and collaborations
  • SWOT analysis of the company - strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023
  • Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies
  • Transcript of an interview by visiongain, for five of the companies.
Discover there what participants achieve, do, and say, helping you stay ahead.

European contract manufacturing organisations

First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:
  • Lonza
  • Evonik Degussa
  • Royal DSM
  • Boehringer Ingelheim Biopharmaceuticals
  • Famar
  • Fareva
  • Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.

Companies based in the US and Japan

Next, our report shows you developments and sales outlooks to 2023 for five other companies:
  • Catalent Pharma Solutions
  • Patheon
  • AbbVie Contract Manufacturing
  • Daito Pharmaceutical
  • Pfizer CentreSource.
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.

Developed-market API specialists

You also discover outlooks for four top producers of active pharma ingredients:
  • Teva API
  • Esteve QuГ­mica
  • Euticals
  • Cambrex.
Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.

India and China - analysis of pharma manufacturing service providers

Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Divis Laboratories
  • Shandong Xinhua Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, seeing what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets

Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.

There you see overall world revenues in 2017 reaching $66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.

Biologics and biosimilars also hold promise. New biological therapies - including antibody-drug conjugates and regenerative medicines - interest CMOs and clients.

Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.

Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you

In particular, our new investigation gives you the following knowledge:
  • Revenues to 2023 for the world CMO market and its components - discover that industry's prospects, finding promising places for investments and revenues
  • Profiles of 30 leading companies - assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations
  • Interviews with 5 companies in the CMO industry - discover debates and opinions to help you stay ahead
  • Competition and opportunities - see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages
  • Outlooks for established players and firms entering the sector - explore needs, practices, and outlooks for future success.
Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Prospects for pharma manufacturing providers - gain by ordering now

Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out - please order our new report now.

AbbVie Contract Manufacturing
Abic (part of Teva)
Activa Capital
Aegerion Pharmaceuticals
Aerofarm (part of Fareva)
Aesica Pharmaceuticals
Agence Nationale de sГcuritГ du MГdicament et des produits de santГ (ANSM) [France]
AgГЄncia Nacional de VigilГўncia SanitГЎria (ANVISA) [Brazil]
Ajinomoto OmniChem
AlgoNomics (part of Lonza)
Alliance Medical Products (part of Siegfried)
Almac Group
Archimica (part of Euticals)
Astellas Pharma
Athera Biotechnologies
Aurobindo Pharma
AuroSource (part of Aurobindo Pharma)
Avalanche Biotechnologies
Banner Pharmacaps (part of Patheon)
Barr-Pliva (part of Teva)
BC Partners
Beijing Double-Crane Pharmaceutical (BDCP)
Bellwyck Packaging Solutions
Bend Research
Bentley Pharma (part of Teva)
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals
Bristol-Myers Squibb
Cardinal Health
Catalent (Shanghai) Clinical Trial Supplies Co
Catalent Pharma Solutions
Celldex Therapeutics
CEVEC Pharmaceuticals
China National Pharmaceutical Group (Sinopharm)
Chirotech Technology (part of Dr. Reddy's Laboratories)
Cleveland BioLabs
Cobra Biologics Holding
CordenPharma (part of ICIG)
CPM ContractPharma (part of Aenova)
Daiichi Sankyo
Daito Pharmaceutical
DecImmune Therapeutics
Delmas Perfusion
DiFUSION Technologies
Divis Laboratories
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals
Durham University
Eclipse Therapeutics (part of Bionomics)
Eindhoven University of Technology
Eli Lilly
Enobia Pharma (now Alexion Pharmaceuticals)
Enzon Pharmaceuticals
Esteve QuГ­mica (part of Esteve)
Euro Vital Pharma (part of Aenova)
European Medicines Agency (EMA)
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Excella (part of Fareva)
Excelvision (part of Fareva)
Farma Lepori (part of Angelini Group)
Farmaclair (part of Fareva)
Farmea (part of Fareva)
Food and Drug Administration (FDA) [US]
Frazier Healthcare
Fuyang Xinghai Investment
Genentech (part of Roche)
GГnГrique MГЄme MГdicament (GEMME) [France]
Genzyme (part of Sanofi)
Gilead Sciences
Gyma Laboratories of America
Haupt Pharma
Health and Safety Executive (HSE) [UK]
Health Canada
Hisun-Pfizer Pharmaceuticals
Human Genome Sciences (part of GSK)
ICI (Imperial Chemical Industries)
Immune Pharmaceuticals
Indoco Remedies
Instituto de Angeli (part of Fareva)
Intellect Neurosciences
International Chemical Investors Group (ICIG)
Ivax API (part of Teva)
JK Pharmaceutical
Laboratoire Aguettant
Laboratoires Besins
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck KGaA
Molecular Partners
National Institutes of Health (NIH) [US]
National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]
New Jersey Institute of Technology
OctoPlus (part of Dr. Reddy's Laboratories)
OmniChem (part of Ajinomoto OmniChem)
OncoMed Pharmaceuticals
Osiris Therapeutics
Otsuka Pharmaceutical
Paranta Biosciences
PFC (now Teva PFC)
Pfizer CentreSource (part of Pfizer)
Piramal Pharma Solutions (part of Piramal Enterprises)
Plantex (part of Teva)
Poli Industria Chimica (part of Euticals)
Prosintex QuГ­mica
R5 Pharmaceuticals (part of Aesica Pharmaceuticals)
Ranbaxy Laboratories (part of Daiichi Sankyo)
Recepta Biopharma
Redwood Bioscience
Respirics (part of Zhejiang Hisun Pharmaceutical)
Royal DSM
Saltigo (part of Lanxess)
Sandoz (part of Novartis)
Sanwa Kagaku Kenkyusho Co
Seattle Genetics
Sentry BioPharma Services
Shandong Xinhua Pharmaceutical (Europe) (part of Shandong Xinhua Pharmaceutical)
Shandong Xinhua Pharmaceutical Co
Shanghai Pharmaceutical Co
Sicor Biotech (part of Teva)
Sigmar Italia (part of Fareva)
Silverfleet Capital
Softigel (part of Procaps)
State Food and Drug Administration (SFDA) [China]
SurModics (part of Evonik Industries)
SwissCo Services (part of Aenova)
Takeda Pharmaceutical Company
Temmler Group (part of Aenova)
Temmler Ireland (part of Aenova)
Temmler Italia (part of Aenova)
Temmler Pharma (part of Aenova)
Temmler Werke (part of Aenova)
Tessenderlo Group
Teva API
Teva Pharmaceutical Industries
ThГramax (part of Teva)
Thermo Fisher Scientific
Tianjin Tianyo Pharmaceuticals
Tianma Tianji
UMN Pharma
University of Bradford
University of Leeds
Valdepharm (part of Fareva)
Vetter Pharma
Vivante GMP Solutions (part of Lonza)
VTU Technology
Wanhuai Beijing Double-Crane Pharmaceutical (part of BDCP)
West Pharmaceutical Services
Xinhua Pharmaceutical (Gaomi) Company (part of Shandong Xinhua Pharmaceutical)
Yiwu Huayi Investment
Zenara Pharmaceuticals
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology
Zibo Xinhua-Perrigo Pharmaceutical Company

Almac Group

Pharmaceutical companies are increasingly looking to cut the number of outsourced service providers that they use and therefore partnering with a company that can offer some clinical trial and manufacturing services will appeal. Almac is not reliant on a small number of clients for its revenue - the company serves more than 600 pharmaceutical partners in over 100 countries. However, there are weaknesses to Almac’s service offering. For example, the company only offers commercial manufacturing of solid dosages, unlike many of its competitors, which also offer manufacturing for other formulations.

Investing in services for biopharmaceutical drug developers will act as a driver for growth for Almac during this decade. Increasing its refrigerated storage capacity and adding pegylation services will increase the number of biologics and biosimilars clients for Almac in the near future.

Pegylation of biological drugs is a common lifecycle management strategy for biological drug developers, particularly in the face of biosimilar competition, which is expected in the coming decade.

During the period 2013-2023, Almac’s contract manufacturing revenue will grow strongly. Revenue grew much faster than the market as a whole between 2008 and 2011, visiongain notes. Growth will slow in the first half of the forecast period, with the company steadily utilising the increased capacity that it has added in recent years, through the addition of new clients. By 2017, Almac’s revenue will have grown to $0.68bn, up from an estimated $0.48bn in 2012. Visiongain believes that in the first half of the period, growth an increased number of companies outsourcing development and manufacturing to Almac will drive growth.

More Publications